-
FDA Approves Groundbreaking All-Oral, Fixed-Duration Treatment for Previously Untreated CLL
NYSE: $ABBV A Significant Advance in Chronic Lymphocytic Leukemia Treatment The U.S. Food and Drug Administration (FDA) has granted approval for the combination treatment of VENCLEXTA® (venetoclax) and acalabrutinib for adult patients newly diagnosed with chronic lymphocytic leukemia (CLL). This pivotal decision, supported by robust data from the Phase 3 AMPLIFY trial, introduces the first…
-
TransCode Therapeutics and Quantum Leap Advance TTX-MC138 Development with IND Amendment Submission for Phase 2a Trial
NASDAQ: $RNAZ A Significant Step Forward in Oncology Treatment TransCode Therapeutics, Inc. and Quantum Leap Healthcare Collaborative (QLHC) have jointly announced a noteworthy progression in their ongoing research and development efforts. The companies have officially submitted an Investigational New Drug (IND) amendment to the U.S. Food and Drug Administration (FDA). This submission pertains to the…
-
ADC Therapeutics Strengthens Team with New Employee Inducement Grants
NYSE: $ADCT ADC Therapeutics SA, a commercial-stage, late-stage biotechnology company focused on the development and commercialization of antibody drug conjugates (ADCs) for patients suffering from cancer, recently announced a significant commitment to its growing workforce. In a filing dated December 17, 2024, the company disclosed the granting of equity awards to newly hired employees under…
-
Anixa Biosciences Advances CAR-T Therapy with U.S. Adopted Name Approval
NASDAQ: $ANIX Anixa Biosciences, Inc., a biotechnology company focused on the development of innovative cancer therapies, has reached a significant milestone in the progression of its CAR-T cell therapy candidate. The company announced that the United States Adopted Names (USAN) Council has approved the non-proprietary name for its novel CAR-T therapy. This approval of a…
-
Hoth Therapeutics Reports Significant Initial Results in Novel Cancer Therapy Trial
NASDAQ: $HOTH A recent press release from PR Newswire highlights exciting early data from Hoth Therapeutics regarding their ongoing clinical study involving a novel treatment approach for cancer patients whose tumors express the Epidermal Growth Factor Receptor (EGFR). The announcement, specifically concerning the open-label pharmacokinetic (PK) cohort of the study, signals a promising step forward…
-
A Significant Step Forward: First U.S. Patient Enrolled in BiPASS Phase 3 Study for Prostate Cancer Diagnosis
NASDAQ: $TLX Today marks an important milestone in the ongoing effort to improve the diagnosis and management of prostate cancer. We are excited to share news regarding the initiation of dosing for the first U.S. patient in the pivotal BiPASS Phase 3 clinical trial. This study focuses on assessing the performance of a novel diagnostic…
-
A New Dawn for DLBCL Treatment? Analyzing Incyte’s Promising Tafasitamab Data
NASDAQ: $INCY The landscape of hematologic oncology is constantly evolving, and recent news from Incyte has sent ripples of excitement through the medical community. Specifically, the announcement of positive topline results from a pivotal study of tafasitamab (marketed as Monjuvi/Minjuvi) as a first-line treatment for Diffuse Large B-Cell Lymphoma (DLBCL) signals a potentially significant step…
-
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors
NASDAQ: $IDYA IDEAYA Biosciences’ recent exclusive license agreement with Hengrui Pharma for SHR-4849 marks a significant milestone in the field of oncology therapeutics. This partnership brings forth a promising novel Phase 1 DLL3 Topo-I-Payload Antibody-Drug Conjugate (ADC) targeting Small Cell Lung Cancer (SCLC) and Neuroendocrine Tumors (NET). The collaboration between these two renowned pharmaceutical companies…
-
Checkpoint Therapeutics Announces FDA Acceptance of BLA Resubmission of Cosibelimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma
NASDAQ: $CKPT Introduction Checkpoint Therapeutics, a leading biopharmaceutical company, recently made a significant announcement regarding the FDA acceptance of the Biologics License Application (BLA) resubmission of Cosibelimab for the treatment of advanced cutaneous squamous cell carcinoma. This development marks a crucial milestone in the ongoing efforts to provide effective treatment options for patients battling this…
-
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolR?-targeted ADC, on January 4, 2024
NASDAQ: $STRO 1. Introduction to Sutro Biopharma’s Investor Webcast Welcome to the article covering the upcoming investor webcast hosted by Sutro Biopharma on January 4, 2024. This webcast aims to highlight the potential multi-cancer opportunity associated with Luvelta, a promising FolR?-targeted Antibody-Drug Conjugate (ADC) developed by Sutro Biopharma. In this article, we will delve into…